Table 2.
Statistical analysis of between-group differences in vismodegib exposure at steady state
| Treatment | n | Geometric LS meansa | Ratio of geometric LS means to Arm A (%)b | 90 % CI for the ratio (%)c | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| AUC0–24h (µmol h/L) | Arm A (vismodegib) | 22 | 402 | |||
| Arm B (vismodegib + rabeprazole) | 24 | 346 | 86.2 | 76.1 | 97.7 | |
| Arm C (vismodegib + itraconazole) | 22 | 388 | 96.4 | 84.9 | 109.6 | |
| Arm D (vismodegib + fluconazole) | 22 | 526 | 130.9 | 115.2 | 148.7 | |
| C ss,ave (µmol/L) | Arm A (vismodegib) | 22 | 16.7 | |||
| Arm B (vismodegib + rabeprazole) | 24 | 14.4 | 86.3 | 76.2 | 97.8 | |
| Arm C (vismodegib + itraconazole) | 22 | 16.2 | 96.5 | 85.0 | 109.7 | |
| Arm D (vismodegib + fluconazole) | 22 | 21.9 | 130.9 | 115.2 | 148.7 | |
ANOVA analysis of variance, CI confidence interval, LS least squares
aGeometric LS means from ANOVA, calculated by transforming the natural log means back to the linear scale
bRatio of geometric LS means back-transformed to the linear scale from the difference calculated on the natural log scale (expressed as a percent)
c90 % CI for ratio of parameter LS means of natural log-transformed parameter (expressed as a percent). Natural log-transformed confidence limits transformed back to the linear scale